Watch the Latest CorrDyn Episode: Mastering Solubility and Stability in Drug Development

How Data and Materials Science Solve Today’s Low-Solubility Drug Challenges

Low-solubility drug products remain one of the most persistent hurdles in modern pharmaceutical development. Overcoming them demands more than traditional formulation intuition—it requires a blend of materials science, deep data rigor, and disciplined experimentation.

On this episode of Data in Biotech, host Ross Katz sits down with Wesley Tatum, Principal Engineer at Serán BioScience, to explore how today’s most advanced formulation teams tackle these challenges using a data-first mindset and modern material-design principles.

Unlocking Solubility Through Amorphous Solid Dispersions (ASDs)

One of the core topics of the discussion is the science behind amorphous solid dispersions. ASDs have become essential tools for improving solubility and bioavailability, especially for today’s increasingly complex small-molecule therapeutics.

Wesley explains how understanding polymer interactions, thermodynamic stability, and long-term manufacturability helps teams design ASDs that not only work in theory, but also survive real-world production constraints.

Why Digital Infrastructure Matters More Than Ever

Modern formulation is no longer just bench work—it's an information discipline.

The conversation highlights how data infrastructure supports:

• Full experiment traceability
• Version control across formulations
• Reproducibility and scientific rigor
• Faster knowledge transfer across client programs

As complexity grows, teams need robust digital systems to avoid the reinvention of work and ensure every formulation decision is backed by trusted, historical data.

Serán’s Integrated Approach to Formulation Bottlenecks

Serán brings together advanced materials expertise, analytical science, and disciplined data practices to help clients move through development bottlenecks.

Wesley and Ross discuss how Serán works with partners to diagnose and resolve challenges such as:

• Poor solubility and bioavailability
• Physical stability concerns
• Manufacturability and scale-up constraints
• Formulation transitions from early R&D through commercial readiness

This comprehensive approach helps companies derisk their development programs and accelerate progress to the clinic.

Where AI and Automation Are—and Aren’t—Useful Yet

The discussion also tackles a timely question: What role does AI realistically play today in formulation science?

Wesley offers a grounded perspective:

• AI and automation already accelerate screening and data organization
• Predictive modeling shows promise for identifying viable formulation spaces
• But… most organizations still lack the volume and quality of standardized data needed for robust, generalizable AI predictions

 In short, the future is coming—but it depends on today’s data discipline.

An Inside Look at the Future of Formulation Science

This episode offers a rare, deep look into how formulation scientists balance performance, manufacturability, stability, and data integrity—all while preparing for an increasingly AI-enabled future.

‍

🎧 Listen and watch the Full Episode

Apple: https://lnkd.in/e3eMWaT6

Spotify: https://lnkd.in/eVmda3xv

YouTube: https://lnkd.in/ewjAythm

‍